The US Food and Drug Administration (FDA) has granted approval to Medtronic鈥檚 SenSight Directional Lead System for deep brain stimulation (DBS) treatment.
Merging the advantages of directionality with sensing power, SenSight assists doctors in offering accurate, personalised DBS therapy for patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It can be used for treating certain symptoms caused by movement disorders such as Parkinson鈥檚 disease, medically refractory epilepsy and dystonia and essential tremor.
DBS treatment involves the transmission of electrical signals from a small device that is similar to a pacemaker. These signals transmit via thin wires called 鈥榣eads鈥� to a targeted location in the brain linked to symptoms of some neurological ailments.
Later, the neurologist will adjust the neurostimulator setting wirelessly after few weeks of surgery to control symptoms effectively and lower possible side effects in a process called programming.
A first directional, sensing-enabled lead, SenSight could boost the identification of local field potentials (LFPs), which are brain signals associated with severe Parkinson’s disease symptoms.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, LFPs are one million times smaller compared to DBS stimulation pulses.
On integrating with the Percept PC device, SenSight works on BrainSense technology to allow doctors to obtain and record improved, directional LFP data from the implanted lead.
After detecting LFPs, doctors can link these brain signals with stimulation and events, capturing medication, symptoms or side effects. This information can help offer tailored and data-driven treatment as well as amend therapy as per patients’ requirements.
Medtronic brain modulation vice-president and general manager Mike Daly said: 鈥淲e are excited to see the clinical benefits that the new SenSight directional lead system will provide to patients and physicians in the US.
鈥淔or over 25 years, Medtronic has driven discoveries and advancements in DBS therapy and we look forward to continuing to deliver meaningful innovation to the movement disorder and epilepsy patient communities.”
While SenSight systems were first implanted at the University of Florida, US, Medtronic is planning a full launch of the device in the country soon.
In March, the SenSight system obtained CE mark and was subsequently launched in Western Europe.
